Yahoo Finance Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth in 2 years. The Dow Jones Industrial Average gained 0.21 percent to close at 26,439.93, while the S&P 500 Index jumped 0.28 percent to close at 2,914.00. The Nasdaq Composite Index climbed 0.65 percent to close at 8,041.97.
''Today's stock market gains look to me like a relief rally following yesterday's Fed meeting. The biggest risk yesterday had been that the 10- and 30-year yields, which were retesting their May highs near 3.12% and 3.24% respectively, would break out on hawkish Fed news which could spark a stock market selloff as occurred back in February,'' according to Colin Cieszynski, chief market strategist at SIA Wealth Management. ''Treasury yields have dropped off since the Fed meeting, taking some of the recent pressure off of stocks and enabling indices to rebound,'' Cieszynski added.
RDI Initiates Coverage on:
bluebird bio, Inc.
https://rdinvesting.com/news/?ticker=BLUE
Regeneron Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=REGN
bluebird bio's stock jumped 4.06% Thursday, to close the day at $144.95. The stock recorded a trading volume of 468,612 shares, which was below its three months average volume of 653,856 shares. In the last year, bluebird bio's shares have traded in a range of 119.90 - 236.17. The share price has gained 20.89% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $154.10 is below its 200-day moving average of $170.90. Shares of bluebird bio have fallen roughly 11.88 percent in the past month and are down 18.61 percent year-to-date.
Access RDI's bluebird bio, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLUE
On Thursday, shares of Regeneron Pharmaceuticals recorded a trading volume of 716,452 shares, which was below the three months average volume of 732,404 shares. The stock ended the day 3.7% higher at $406.00. The share price has fallen 14.88% from its 52 week high with a 52 week trading range of 281.89 - 477.00. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $386.42 is above its 200-day moving average of $344.49. Shares of the company are trading at a Price to Earnings ratio of 29.48. Shares of Regeneron Pharmaceuticals have gained roughly 4.52 percent in the past month and are up 7.99 percent year-to-date.
Access RDI's Regeneron Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=REGN
Our Actionable Research on bluebird bio, Inc. (BLUE) and Regeneron Pharmaceuticals, Inc. (REGN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
